Archives: 2/2006

14154655 The Diet SpudBBC News is reporting that potato known as Vivaldi (available at Sainsbury’s in the UK) has been found to contain 1/3 less calories than other potato varieties.

Since nutritional values can differ among potatoes, the Vivaldi can have up to 38% less carbohydrate and 56% fewer calories than other varieties., the producers say.
The potato, which has normal levels of vitamin C and other nutrients, was originally developed from seed for a creamy taste by Naturally Best of Lincolnshire.

Link

The FDA’s Center for Devices and Radiological Health (CDRH), great overseer of all medgadgets (at least in the US), has released their 510(k) decisions for the month of January.
If you’re a member of an involved party, you should have received a letter by now. However, this might be a good way to see what your competition is up to.
Link to the CDRH

While many are staying tied to their TVs anxiosly awaiting to hear if their personal cell phone was tapped by the government, or if Kwan will skate, I’m anxiously watching the results of the worldwide RIM mess.
7341 Blackberry Shut Down and the Doctors/Patients That May SufferMy interest not only stems from the fact that I’m a past Blackberry owner, but from the fact that I can’t stop thinking about all the healthcare personnel that are not only addicted to their email, but that depend on it as part of their practice and/or healthcare system. An interesting article is posted at NetworkWorld. I recommend giving it a read, and thinking about the ramifications of a RIM shut down. Sure it may keep your phone from getting tapped, but it may also keep your GP from knowing nephrotic from nephritic!

Skyscape and the American Society of Health-System Pharmacists (ASHP) have joined forces to offer special value bundles for the American Hospital Formulary Service (AHFS) Drug References for PDA. There are three special value packages available, depending on which of the four AHFS reference titles are desired: AHFS Drug Information, AHFS DI Essentials, FamilyRx, or RxDrugs. The multi-title packages represent a discount of up to a 30% over purchasing the titles individually. For students and new practitioners, ASHP offers even greater discounts. Email marketing@ahfs.org for details.
AHFS AHFS Drug Reference Packages    Special Student DiscountsThrough the fast, dependable smARTlink™ technology of Skyscape, AHFS now offers drug information in a quick and user friendly PDA format. Skyscape’s flexible interface enables you to answer most questions in 20 seconds or less without hunting through pages of monographs or shifting between applications; it’s the fastest route to the most up-to-date drug information available.

All of Skyscape’s products are designed for Palm and Pocket PC operating systems, and many are also designed for Windows desktop, laptop, and tablet use. The company offers free trial versions of the AHFS Drug References and related products here.

20060207 Isabelle Face Transplant Patient Goes PublicWe’ve covered her before. Isabelle Dinoire, a French woman mauled by her dog received a allograft transplant on November 27th, 2005.

In a press conference before scores of journalists and television cameras, Isabelle Dinoire, 38 – whose name had previously been kept secret under French law – said she was making good progress since the ground-breaking surgery, and hoped to return to work. “Since my operation I have a face, like everyone. I will be able to resume a normal life,” she said.
Dinoire, wearing a black top and pink cardigan, paid tribute to the family of the donor who had given its consent to the graft, and to the surgical team that carried out the operation. “My operation will enable others to live again,” she said.
The November 27 operation was conducted by Bernard Devauchelle, a professor of facial surgery at the Amiens hospital. He worked with Jean-Michel Dubernard, a surgeon at the Edouard Herriot hospital in Lyon and a French deputy, who performed the world’s first hand transplant in September 1998, followed by the first double hand and forearm transplant in January 2000.
The team that carried out the transplant said on Monday that it asked the French health authorities for permission to carry out five similar operations in the future. “We want to launch these new techniques to give hope to other people all over the world,” said Jean-Michel Dubernard, a surgeon at the Edouard Herriot hospital in Lyon and a French deputy, who helped lead the surgical team.

Given the sensitivity of the issue, it seems good that she was kept away from the public eye for some time. After the psychological stress of the injury and receiving part of a donor’s face, a horde of photographers would have been pretty onerous. Of course, she’s bound to be on Oprah any day now.
Link

3214154 Web Project to Help Scientists Combat Influenza
Reactome, a curated knowledgebase of biological pathways, is a Web-based project that tries to bring together core pathways and reactions in human biology. According to the press release from UT Southwestern Medical Center, this project’s ability to look into influenza-host lifecycles might help scientists to develop new methods of combating the flu:

The on-line map, part of a project called Reactome, is intended to teach scientists about parts of the influenza lifecycle they might not be familiar with, and to help researchers look at specific reactions and figure out ways to block them.
“Understanding how influenza reacts with its host is really critical for the rational design of anti-viral drugs and new vaccines,” said Dr. Richard Scheuermann, professor of pathology at UT Southwestern.
Reactome, online at www.reactome.org, was created in 2004 and includes a variety of biochemical pathways for processes such as cell death in several species, primarily human.
Individual reactions are shown as separate items, which are linked by arrows to associated reactions. The diagrams resemble constellations; hence the “starry sky” nickname.
The influenza pathway component and a simultaneous HIV database going online mark the first time Reactome has displayed interactions between an infectious pathogen and its host, Dr. Scheuermann said.
Pathogens such as influenza have evolved to use hosts to promote their growth, while at the same time blocking the host reactions that recognize and respond to infection. Each year, for example, winter is marked by the outbreak of flu caused by new viruses that the human immune system doesn’t recognize.
The new Reactome influenza database outlines a typical virus life cycle, which will be updated as more research becomes available.
“In the future, the goal is to build out all of the host-pathogen reactions,” Dr. Scheuermann said.

The press release
The Reactome Project

123421235 New Testing Method to Assess Health Risks of Grey GooUCLA researchers have developed a new testing method that would allow to assess health safety of novel nanomaterials. The research completed by the team of Dr. Andre Nel, professor of medicine at the David Geffen School of Medicine at UCLA and a member of the California NanoSystems Institute, has been reviewed in the article in the Feb. 3 issue of the journal Science:

The testing model developed at UCLA is based on toxicity testing for occupational and air pollution particles, which include nanoparticles. Nanoparticles are the most toxic ingredient in these environmental pollutants. A mature toxicological science has emerged from the study of these particles, providing a framework for a predictive testing strategy applicable to engineered nanomaterials.
A predictive strategy is one in which a series of simple but high-quality tests can be employed to predict which materials could be hazardous, and therefore speed up the process of classifying materials into those that are safe and those that could pose toxicity problems. This type of approach is similar to that used by the National Toxicology Program for evaluation of chemical agents.
Nel’s model predicts toxicity according to the ability of some nanoparticles to generate toxic oxygen radicals, which are highly reactive forms of oxygen that can cause tissue injury, including inflammation and other toxic effects. For air pollution particles, this injury can translate into asthma and atherosclerotic heart disease. Using this model, Nel’s laboratory has developed a series of tests to assess nanoparticle toxicity in non-biological environments as well as in tissue cultures and animal models.
“We can use the strong scientific foundation of air pollution particle testing to help understand the health impact of engineered nanoparticles and ensure safe manufacturing of nanoproducts,” said Nel, who also is the co-director of the Southern California Particle Center and the UCLA Asthma and Immunological Disease Center.
The review in Science addresses questions about occupational and inhalation exposures to nanoparticles and outlines the properties of nanomaterials that need to be considered for toxicity testing.
The impact of nanoparticle interactions with the body is dependent on their size, chemical composition, surface structure, solubility, shape and how the individual nanoparticles amass together, according to Nel. Nanoparticles may modify the way cells behave and potential routes of exposure, include the gastrointestinal tract, skin and lungs. The three key elements of the toxicity screening strategy should include the physical and chemical characterization of nanomaterials, tissue cellular assays and animal studies.
“An understanding of nanotoxicity could also lead to the harnessing of their properties such as using nanoparticles that initiate cell death to be used for targeted chemotherapy approaches,” said Nel, who also leads the Cellular Immunology Activation Laboratory in UCLA’s Jonsson Cancer Center.

The UCLA press release

ENT

phonak micro The microSaviamicroSavia is an ultra-slim, “feather-light” hearing aid, designed to essentially disappear behind the ear, and equipped with a transparent micro tube leaving the ear open. The manufacturer promises “an astonishing long battery life.”
This one comes from Phonak UK, maker of innovative digital hearing systems. The company believes that its Savia line of hearing aids, powered by Digital Bionics technology, provides “effortless hearing in all environments.”
Some features of the system, from the company’s website:

The 10 world firsts of Savia
Its 10 world firsts make Savia powerful and versatile. They enable Savia to address the toughest challenges and to create a natural sound quality. Effortless hearing is now possible even in difficult hearing situations.
# 1 SoundNavigation
Automatic performance that fades smoothly between 4 base programs for optimal performance in all environments.
# 2 Real Ear Sound
Restores front-to-back localization and natural sound perception with 20 channel resolution.
# 3 EasyFM
Savia recognizes the presence of an FM signal and activates the FM program automatically.
# 4 Digital SurroundZoom
The multi-microphone technology splits the incoming signals into 20 channels and suppresses the strongest noise source in each channel.
# 5 DataLoggingplus
Provides access to your client’s real life use of amplification and proposes optimal volume corrections per base program.
# 6 EchoBlock
Reinstates effortless hearing by removing the reverberant components of the signal and restoring important speech cues.
# 7 Dual Wind Noise Management
The Wind & Weather Microphone Protector significantly reduces turbulences caused at the inlet and the electronic Wind Noise Suppressor suppresses the remaining noise.
# 8 Smallest FM receiver
The ML9S is not only completely design-integrated but also the world’s smallest FM receiver.
# 9 Smallest, most powerful chipset
The heart of Savia is the world’s smallest, most powerful digital signal processor manufactured in state-of-the-art submicron technology, with more than 6,000,000 transistors packed into a chip the size of 2.7 x 3.7 mm.
# 10 Three field-replaceable volume control options
Savia offers three field-replaceable, easily exchanged volume control options to suit all client needs: ergonomics, minimal visibility or no VC at all.

More here
microSavia Professional Brochure (.pdf)
(hat tip: Gizmodo)

turnturnturn Turn the Other CheekWith inventions like The Rascal and the HarmonySystem, we suppose it was inevitable that an inventor would tackle the problem of pressure sores in the elderly and infirm.
And so, we commend the Turnamatic for its brilliance, while at the same time lamenting the dignity of the patients, who will be treated like rotisserie-style chickens as they sleep:

Six strategically placed inflatables on an alternating pressure, low air loss mattress will not merely tilt, but it will laterally turn an immobile, bedridden patient from one complete side to the other!

The concept is so easy to understand, and the potential for mockery is so great, they pretty much had to include a video.
This device could soon find its place in nursing homes and hospitals across the country (the Turnamatic Foundation is looking for investors). But we anticipate we’ll see this on late-night TV, with a 1-800 number and perhaps this Bonnie Tyler song playing in the background (on second thought, this tune may be a better fit).
The Turnamatic inventor goes on to claim, “An automatic turn is gentler, less intrusive, as well as less abrasive than a manual turn.”
Are we talking about turns or something else?